ZVSA: Prakiraan wutah bathi kanggo taun ngarep ZyVersa

The current consensus EPS growth forecast for next year demonstrates the resilience of ZyVersa Therapeutics (ZVSA), which remains shielded from global shocks. ZyVersa Therapeutics (ZVSA) relies on the uniqueness of the IC 100 molecule that blocks kidney fibrosis, providing the company with significant pricing power. The asset's value is based on patents, as the medical need remains constant. The parameter value is 0.00, serving as a key benchmark for future revenues.
Rincian metrik lan analitis perusahaan ZyVersa Therapeutics (ZVSA)

This indicator reflects the expected percentage change in earnings per share, calculated as the difference between the consensus forecast for the future period and the current actual EPS value. Analyzing the EPS growth prospects for the next fiscal year allows for an assessment of ZyVersa Therapeutics (ZVSA) potential amid early-stage clinical trials, where future profitability depends directly on the success of molecule testing and the maintenance of liquidity.